Smell Changes & Efficacy of Nasal Theophylline (SCENT)
Olfactory Disorder, Anosmia, Viral Infection
About this trial
This is an interventional treatment trial for Olfactory Disorder focused on measuring Olfactory dysfunction, Anosmia, Hyposmia, Post-viral, Theophylline, Adverse effects, Smell
Eligibility Criteria
Inclusion Criteria:
- Subjective or clinically diagnosed olfactory dysfunction of 6 months to 36 months duration after a presumed viral upper respiratory infection
- Ability to read, write, and understand English
Exclusion Criteria:
- Dependence on theophylline for comorbid conditions such as asthma and chronic obstructive pulmonary disease
- History of an allergic reaction to theophylline or other methylxanthines
- Prior sinonasal or anterior skull base surgery
- Nasal polyposis
- History of neurodegenerative disease (ie. Alzheimer's dementia, Parkinson's disease, Lewy body dementia, frontotemporal dementia)
- Pregnant or breastfeeding mothers
- Current use of medications with significant (≥40%) interactions with theophylline, which include cimetidine, ciprofloxacin, disulfiram, enoxacin, fluvoxamine, interferon-alpha, lithium, mexiletine, phenytoin, propafenone, propranolol, tacrine, thiabendazole, ticlopidine, and troleandomycin
Sites / Locations
- Washington University in St. Louis
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Theophylline saline irrigation
Placebo saline irrigation
Theophylline 12 mg capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.
Identical-appearing lactose monohydrate capsule contents dissolved into a sinus rinse bottle containing distilled or boiled tap water and USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets, delivered to the bilateral nasal cavities twice daily.